Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity
The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
1. A method of treating MS, comprising:
administering to a subject in need thereof a therapeutically effective amount of:
N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine (1); 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one (2); or a pharmaceutically acceptable salt, a pharmaceutically acceptable tautomer, or a pharmaceutically acceptable stereoisomer thereof.
2. The method according to claim 1 , wherein the MS is selected from relapsing MS (RMS), relapsing-remitting MS (RRMS), progressive MS (PMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), and progressive-relapsing MS (PRMS).
3. A method of preventing MS, comprising
administering to a subject in need thereof an effective amount of N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine (1); or 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one (2) or a pharmaceutically acceptable salt, a pharmaceutically acceptable tautomer, or a pharmaceutically acceptable stereoisomer thereof.
4. The method according to claim 3 , wherein the MS is selected from relapsing MS (RMS), relapsing-remitting MS (RRMS), progressive MS (PMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), and progressive-relapsing MS (PRMS).